Embla Medical hf (CPSE:EMBLA) - Prezzo delle azioni, notizie e analisi

EMBLA Panoramica delle azioni

Embla Medical hf., insieme alle sue controllate, fornisce prodotti ortopedici non invasivi in Europa, Medio Oriente, Africa, Americhe e Asia-Pacifico. Maggiori dettagli

EMBLA analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	5/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Negoziato a 13.1% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 16.88% all'anno

Gli utili sono cresciuti del 32.1% nell'ultimo anno

Analisi del rischio

Ha un alto livello di debito

Embla Medical hf. Concorrenti

Ambu

CPSE:AMBU B

DKK 31.7b

Demant

CPSE:DEMANT

DKK 57.6b

NuVasive

NasdaqGS:NUVA

US$2.1b

CONMED

NYSE:CNMD

US$2.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Embla Medical hf
Prezzi storici delle azioni
Prezzo attuale dell'azione	DKK 35.60
Massimo di 52 settimane	DKK 36.60
Minimo di 52 settimane	DKK 26.00
Beta	0.63
1Variazione di 1 mese	5.33%
Variazione a 3 mesi	15.21%
Variazione di 1 anno	30.40%
3Variazione a 3 anni	-16.73%
Variazione a 5 anni	-28.80%
Variazione dall'IPO	547.27%

Notizie e aggiornamenti recenti

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 25

Recent updates

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 25

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Oct 17

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Oct 02

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Aug 22

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 26

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Jul 17

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Apr 10

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Mar 23

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Jan 21

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 03

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Nov 28

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Nov 08

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

Sep 23

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Aug 21

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Jul 18

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 14

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

May 19

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Mar 14

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 21

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Feb 03

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Nov 25

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Oct 17

Is Össur hf (CPH:OSSR) A Risky Investment?

Sep 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Aug 21

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Jul 11

Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly

May 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

May 07

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Mar 25

We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right

Mar 02

We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt

Feb 22

Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?

Feb 09

Rendimenti per gli azionisti

	EMBLA	DK Medical Equipment	DK Mercato
7D	-1.1%	-1.2%	-3.1%
1Y	30.4%	16.5%	5.7%

Ritorno vs Industria: EMBLA ha superato il Danish Medical Equipment che ha restituito 16.5 % nell'ultimo anno.

Rendimento vs Mercato: EMBLA ha superato il mercato Danish che ha restituito 5.7 % nell'ultimo anno.

Volatilità dei prezzi

Is EMBLA's price volatile compared to industry and market?
EMBLA volatility
EMBLA Average Weekly Movement	3.3%
Medical Equipment Industry Average Movement	3.7%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Prezzo delle azioni stabile: EMBLA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di EMBLA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1971	4,000	Sveinn Solvason	www.emblamedical.com

Embla Medical hf., insieme alle sue controllate, fornisce prodotti ortopedici non invasivi in Europa, Medio Oriente, Africa, Americhe e Asia-Pacifico. Opera attraverso tre segmenti: Protesi, Bracing & Supports e Patient Care. Il segmento Protesi offre prodotti meccanici, come protesi per arti inferiori e protesi per dita, e prodotti bionici controllati da microprocessore per piedi, ginocchia, mani, guaine, dita e altri componenti integrati.

Embla Medical hf. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Embla Medical hf con la sua capitalizzazione di mercato?
EMBLA statistiche fondamentali
Capitalizzazione di mercato	DKK 15.07b
Guadagni(TTM)	DKK 489.38m
Ricavi(TTM)	DKK 5.95b

31.1x

Rapporto P/E

2.6x

Rapporto P/S

EMBLA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
EMBLA Conto economico (TTM)
Ricavi	US$840.31m
Costo del fatturato	US$319.17m
Profitto lordo	US$521.13m
Altre spese	US$452.07m
Guadagni	US$69.07m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

Feb 05, 2025

Utile per azione (EPS)	0.16
Margine lordo	62.02%
Margine di profitto netto	8.22%
Rapporto debito/patrimonio netto	50.7%

Come si è comportato EMBLA nel lungo periodo?

Vedi performance storica e confronto

EMBLA Panoramica delle azioni

Premi

Analisi del rischio

Embla Medical hf. Concorrenti

CPSE:AMBU B

DKK 31.7b

CPSE:DEMANT

DKK 57.6b

NasdaqGS:NUVA

US$2.1b

NYSE:CNMD

US$2.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Now 21% undervalued

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Recent updates

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Now 21% undervalued

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Price target decreased to kr.42.00

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Price target decreased to kr.43.70

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price